Cell Substrates and Engineering
We provide tailored solutions for recombinant cell line generation, expression modulation, gene editing and reporter cell line development, supporting target validation, drug screening and mechanistic studies. Our extensive, continually updated in-house catalogue includes a wide range of pre-developed cell lines.
Drug development depends on the use of a wide variety of cell types, which are critical for evaluating the potential success of new therapeutics. These include primary cells from healthy individuals or patients, which can be used directly, expanded, differentiated, activated, or engineered based on experimental goals. Continuous cell lines have long been foundational to bioassay design, offering reliable and consistent performance over time. Like primary cells, these cell lines can be used in their native form or engineered to express or silence target proteins, signalling pathways, or include reporter constructs to meet specific study objectives.
Sourcing optimal cell types can be challenging due to ethical approvals, licensing requirements, and the availability of commercial lines with relevant targets. Given the complexity of new therapeutics and regulatory demands, obtaining high-performing cell lines is critical.
Through our partnerships, we access high-quality primary cells and tissues from both patients and healthy donors. We also maintain substantial stocks of well-characterised cells onsite, sourced from diverse donors. Our extensive collection of purified immune cells further strengthens our services, and we specialise in engineering complex cell lines and creating customized solutions to address your specific challenges.
Find out more about our Cell Line Development Capabilities
Unlock advanced cell line development capabilities with custom approaches. We specialise in creating cell lines for cell-based functional assessments.
ACCESS THE TECHNICAL PRESENTATION